Pfizer's Xtandi Delays Prostate Cancer Spread In Early Stage Disease

Data shows that it took 36.6 months for the disease to spread to other parts of the body in patients who received Xtandi plus ADT

USE OF Xtandi in early stage prostate cancer on top of standard hormone therapy reduced the risk of disease spreading or death by 71 per cent compared with hormone therapy alone, study results that could lead to significantly increased sales of the Pfizer and Astellas Pharma medicine.

The data from a highly anticipated study released recently showed that it took 36.6 months for the disease to spread to other parts of the body in patients who received Xtandi plus androgen deprivation therapy (ADT), a measure known as median metastasis free survival. That compared with 14.7 months for ADT alone, a highly statistically significant difference of nearly two years.

Subjects in the 1,400-patient study were deemed at elevated risk of developing metastases in the bones or elsewhere.